Thor Halfdanarson talks about the multidisciplinary care approach to treating patients with neuroendocrine tumors (NETs), imaging techniques for initial staging, restaging and monitoring the effectiveness of treatment in NET patients, the variations in the treatment guidelines for NETs between Europe and the USA and the main takeaways from ENETS 2024. 

Wouter de Herder explains the critical role of endocrinology in managing patients with neuroendocrine neoplasms, the principles of somatostatin analog therapy and identifies the groups of neuroendocrine tumor (NET) patients who benefit most from it, the recommended second-line treatment for patients with advanced, unresectable, or metastasized gastroentero-pancreatic NET after recurrence with somatostatin analogs, and the main highlights from ENETS 2024.

Paola Erba discusses the use of FDG PET/CT in conjunction with somatostatin receptor imaging for the initial staging of patients with neuroendocrine tumors, how the recent developments in theranostics have influenced guidelines and recommendations for treating neuroendocrine tumors (NETs), the challenges and needs for expanding access to radiopharmaceutical treatment (RPT), and the main highlights from the ENETS 2024.